Online citations, reference lists, and bibliographies.
← Back to Search

Use Of Computed Tomography And Positron Emission Tomography/Computed Tomography For Staging Of Local Extent In Patients With Malignant Pleural Mesothelioma

T. Frauenfelder, P. Kestenholz, R. Hunziker, T. L. Nguyen, Martina Fries, P. Veit-Haibach, L. Husmann, R. Stahel, W. Weder, I. Opitz
Published 2015 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Purpose The objective of this study was to determine the diagnostic value of computed tomography (CT) and positron emission tomography (PET)/CT for staging of malignant pleural mesothelioma (MPM) in patients undergoing induction chemotherapy. Methods Sixty-two patients (median age, 61 years; female: n = 9) with proven MPM underwent CT after induction chemotherapy. Of these, 28 underwent additional PET/CT. Extrapleural pneumonectomy was performed for pathological TNM staging. Clinical TNM stage was assessed by 3 independent readers. Relative and absolute underestimation and overestimation were compared with pathological tumor stage. Sensitivity, specificity, and accuracy for differentiation between stages T2 and T3 were assessed. Interobserver agreement between the readers was analyzed (&kgr;). Results Positron emission tomography/CT and CT underestimated T stage in up to 30% of the cases. Positron emission tomography/CT had a higher accuracy for tumor extent compared with CT (PET/CT: 0.92; CT: 0.84). The accuracy for nodal staging was higher for CT than for PET/CT (PET/CT: 0.78; CT: 0.87). Concerning International Mesothelioma Interest Group classification, PET/CT improved the accuracy of preoperative staging compared with CT (PET/CT: 0.91; CT: 0.82). Interobserver agreement was moderate for CT (0.48–0.62) and good for PET/CT (0.64–0.83) for T staging. For nodal staging, interobserver agreement was fair to moderate for CT and good for PET/CT (CT: 0.37–0.51; PET/CT: 0.73–0.76). Conclusions Positron emission tomography/CT is more accurate and has a lower interobserver variability for clinical intrathoracic staging of MPM compared with CT. Nevertheless PET/CT underestimated tumor stage in a substantial number of cases, showing the need for a more accurate imaging technology or approach.
This paper references
10.1136/thx.31.1.15
Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients.
E. Butchart (1976)
10.2214/AJR.172.4.10587144
Staging of malignant pleural mesothelioma: comparison of CT and MR imaging.
R. Heelan (1999)
10.1055/s-0029-1241029
Integrated positron emission tomography-computed tomography does not accurately stage intrathoracic disease of patients undergoing trimodality therapy for malignant pleural mesothelioma.
J. Pilling (2010)
10.1016/j.lungcan.2013.08.005
Imaging in pleural mesothelioma: a review of the 11th International Conference of the International Mesothelioma Interest Group.
S. Armato (2013)
10.1510/icvts.2010.255893
What is the best way to diagnose and stage malignant pleural mesothelioma?
I. Zahid (2011)
10.1016/J.EJRAD.2004.05.007
Fast T1- and T2-weighted pulmonary MR-imaging in patients with bronchial carcinoma.
M. Both (2005)
10.1097/RLI.0b013e3181817b3d
Computed Tomography, Positron Emission Tomography, Positron Emission Tomography/Computed Tomography, and Magnetic Resonance Imaging for Staging of Limited Pleural Mesothelioma: Initial Results
C. Plathow (2008)
10.2307/2529786
An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers.
J. Landis (1977)
10.1016/j.ejrad.2009.01.021
Thin-section CT of the mediastinum in preoperative N-staging of non-small cell lung cancer: comparison with FDG PET.
A. Nambu (2010)
10.1378/CHEST.108.4.1122
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
V. Rusch (1995)
10.1097/JTO.0b013e31824ab6c5
Pleurectomy/Decortication is Superior to Extrapleural Pneumonectomy in the Multimodality Management of Patients with Malignant Pleural Mesothelioma
L. Lang-Lazdunski (2012)
10.1158/1078-0432.CCR-10-2873
Thymidylate Synthase and Excision Repair Cross-Complementing Group-1 as Predictors of Responsiveness in Mesothelioma Patients Treated with Pemetrexed/Carboplatin
P. A. Zucali (2011)
10.1016/j.ejcts.2008.07.050
Preoperative staging of mesothelioma by 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography fused imaging and mediastinoscopy compared to pathological findings after extrapleural pneumonectomy.
J. Sørensen (2008)
10.1097/JTO.0b013e3181ed0489
A Systematic Review of Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma
C. Cao (2010)
10.1016/J.EJRAD.2007.08.010
Morphologic and functional imaging of malignant pleural mesothelioma.
M. Yamamuro (2007)
American Joint Committee of Cancer. AJCC Cancer Staging Manual
(2010)
10.1016/J.LUNGCAN.2005.03.008
Malignant pleural mesothelioma: staging systems.
P. V. Schil (2005)
10.1053/j.ro.2013.03.017
Malignant pleural mesothelioma: role of CT, MRI, and PET/CT in staging evaluation and treatment considerations.
M. Truong (2013)
10.1097/JTO.0b013e3182730e0e
Robust data: the essential foundation of a revised staging system for pleural mesothelioma.
H. Kindler (2012)
10.1097/JTO.0b013e31826915f1
Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database
V. Rusch (2012)
10.1007/978-3-642-82982-6
TNM Classification of Malignant Tumours
L. Sobin (1987)
10.1183/09031936.00146110
Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma?
T. Frauenfelder (2011)
10.1378/CHEST.123.1_SUPPL.137S
Noninvasive staging of non-small cell lung cancer: a review of the current evidence.
E. Toloza (2003)
10.1016/S0022-5223(03)00207-1
Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma.
R. Flores (2003)
10.1097/00130404-200311000-00008
Promising Early Local Control of Malignant Pleural Mesothelioma Following Postoperative Intensity Modulated Radiotherapy (IMRT) to the Chest
A. Ahamad (2003)
10.1016/J.JTCVS.2004.10.034
Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications.
J. Erasmus (2005)
10.1200/JCO.1993.11.6.1172
Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma.
D. Sugarbaker (1993)



This paper is referenced by
10.1053/j.sult.2017.07.006
Malignant Pleural Mesothelioma: Diagnosis, Staging, Pitfalls and Follow-up.
Erika G Odisio (2017)
Risk factors and biomarkers for malignant mesothelioma
Vasiliki Panou (2019)
10.1016/j.cllc.2020.06.002
Delayed-Phase Enhancement for Evaluation of Malignant Pleural Mesothelioma on Computed Tomography: A Prospective Cohort Study.
Akash M Patel (2020)
10.5152/tcb.2015.060
Pet Applications For Staging And Restaging In Thoracic Malignancies
T. Ones (2015)
10.1016/j.lungcan.2016.01.017
Diagnostic accuracy of sequential co-registered PET+MR in comparison to PET/CT in local thoracic staging of malignant pleural mesothelioma.
K. Martini (2016)
10.1016/j.lungcan.2018.11.033
Imaging in pleural mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group.
S. Armato (2019)
10.1097/JTO.0000000000000614
In Response.
A. Billè (2015)
10.1136/thoraxjnl-2017-211321
British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma
I. Woolhouse (2018)
10.21037/shc-20-64
The role of extrapleural pneumonectomy for malignant pleural mesothelioma: reviewing 20-years of experience
Raphael Werner (2020)
10.14356/KONA.2016014
Aerosol Delivery of siRNA to the Lungs. Part 1: Rationale for Gene Delivery Systems.
Susanne R. Youngren-Ortiz (2016)
10.1183/13993003.01428-2016
Impact of tumour thickness on survival after radical radiation and surgery in malignant pleural mesothelioma
M. D. de Perrot (2017)
10.1093/annonc/mdy195
Pleural mesothelioma: is the surgeon still there?
I. Opitz (2018)
10.1016/J.EJRNM.2016.12.011
Value of contrast CT in combination with PET/CT in mesothelioma staging: Optimal protocol for initial assessment
M. Houseni (2017)
10.23750/abm.v88i2.5558
Diagnostic imaging and workup of malignant pleural mesothelioma
L. Cardinale (2017)
10.1259/bjr.20170814
18F-FDG PET/CT in the management of patients with malignant pleural mesothelioma being considered for multimodality therapy: experience of a tertiary referral center.
H. S. Elliott (2018)
10.1007/978-3-030-16884-1_11
Role of Metabolic Imaging in Mesothelioma
Fabrizia Gelardi (2019)
10.21037/atm.2017.03.97
Overview of treatment related complications in malignant pleural mesothelioma.
D. Murphy (2017)
Semantic Scholar Logo Some data provided by SemanticScholar